Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ ´º½º·¹ÅÍ ±¹¹® Å×½ºÆ®ÆÄÀÏ
|
|
|
ÀϺΰ³Á¤ |
ÀǾàÇ° Ç¥½Ã µî¿¡ °üÇÑ ±ÔÁ¤ ÀϺΰ³Á¤°í½Ã
°¡. ¼ÒºñÀÚÀÇ °¡µ¶¼º Á¦°í¸¦ À§ÇØ ÀϹÝÀǾàÇ° Ç¥Áؼ½Ä ¸¶·Ã(Á¦6Á¶ÀÇ2, µµ 1, µµ 2)
³ª. ¾à»ç¹ý °³Á¤¿¡ µû¸¥ °í½Ã Á¶¹® Á¤ºñ(Á¦7Á¶, Á¦7Á¶ÀÇ2, Á¦9Á¶)
´Ù. ±âÀç»çÇ× È°ÀÚÅ©±â È®´ë ±ÇÀå(Á¦9Á¶)......´õ º¸±â |
|
ÀϺΰ³Á¤ |
ÀǾàÇ° ºÎÀÛ¿ë ÇÇÇر¸Á¦±Þ¿© Áö±Þ Á¦¿Ü ´ë»ó ÀǾàÇ°ÀÇ ÁöÁ¤ ÀϺΰ³Á¤°í½Ã
ÀǾàÇ° ºÎÀÛ¿ë ÇÇÇر¸Á¦±Þ¿© Áö±Þ Á¦¿Ü ´ë»ó ¹üÀ§¸¦ ÁöÁ¤ÇÔ¿¡ ÀÖ¾î ±× °£ ¿î¿µ »ó ÀϺΠ¹ÌºñÁ¡À» °³¼± ¹× º¸¿ÏÇÏ°í, ¡¸ÀǾàÇ° ºÎÀÛ¿ë ÇÇÇر¸Á¦±Þ¿© Áö±Þ Á¦¿Ü ´ë»ó ÀǾàÇ°ÀÇ ÁöÁ¤¡¹Á¦3Á¶(Àç°ËÅä±âÇÑ)¿¡ µû¸¥ µ¿ ±ÔÁ¤ÀÇ °³Á¤ µîÀÇ Á¶Ä¡¸¦ ÃëÇÏ°íÀÚ ÇÔ.
°¡. ºÎÀÛ¿ë ÇÇÇر¸Á¦ Á¦¿Ü ±âÁØÀ» Ãß°¡ÇÏ¿© ±âÁØ ¸íÈ®È(¾È Á¦2Á¶Á¦1Ç×)
³ª. ÇÇÇر¸Á¦ Á¦¿Ü ÀǾàÇ° ¼ººÐ ¸ñ·Ï »èÁ¦ ¹× °ø°í ÀýÂ÷ Ãß°¡(¾È Á¦3Á¶)...... ´õ º¸±â |
|
|
ÀϺΰ³Á¤ |
¡¸º¹ÇÕ¤ýÁ¶ÇÕÇ°¸ñ 󸮱ÔÁ¤¡¹ÀϺΰ³Á¤¿¹±Ô
ÇöÀçÀÇ °úÇÐ ¼öÁØÀ» ¹Ý¿µÇÏ¿© º¹ÇÕ¡¤Á¶ÇÕ Ç°¸ñ¿¡ ´ëÇÑ ºÐ·ù ±âÁØ ¹× ¹Î¿øó¸® ¼¼ºÎÀýÂ÷ µîÀ» ¸¶·ÃÇÏ°í ±× °£ ¿î¿µ»ó ³ªÅ¸³ ÀϺΠ¹ÌºñÁ¡À» °³¼±ÇÏ°íÀÚ ÇÔ
°¡. º¹ÇÕ¡¤Á¶ÇÕÇ°¸ñÀº ¾Æ´Ï³ª ±âÁ¸ »ç·Ê°¡ ¾ø¾î ºÐ·ù°¡ ºÒºÐ¸íÇÑ Ç°¸ñ¿¡ ´ëÇÑ ºÐ·ù ÀýÂ÷ ½Å¼³(Á¦3Á¶, Á¦7Á¶)
³ª. ÃÖ±Ù ±â¼úÀ» ¹Ý¿µÇÑ º¹ÇÕ¡¤Á¶ÇÕÇ°¸ñÀÇ ºÐ·ù»ç·Ê Ãß°¡(Á¦4Á¶)
´Ù. Ç°¸ñÁ¶Á¤¼ÒÀ§¿øȸ ½Å¼³(Á¦14Á¶) ...... ´õ º¸±â |
|
ÀÇ°ßÁ¶È¸ |
¡¸¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å Ä¡·á º¹ÇÕÁ¦ °³¹ß °ü·Ã ÁúÀÇÀÀ´äÁý¡¹(¾È) ÀÇ°ßÁ¶È¸ (~8/7±îÁö)
ÁÖ¿ä³»¿ë
- ÀϹݻçÇ׿¡ °üÇÑ ÁúÀÇÀÀ´ä
- ¾ÈÀü¼º,À¯È¿¼º ÀÚ·á Á¦Ãâ ¹üÀ§¿¡ °üÇÑ ÁúÀÇÀÀ´ä
- ¾à¹°»óÈ£ÀÛ¿ë½ÃÇè ¹× »ý¹°ÇÐÀûµ¿µî¼º½ÃÇèÀÚ·á¿¡ °üÇÑ ÁúÀÇÀÀ´ä
- Ä¡·áÀû È®Áõ ÀÓ»ó½ÃÇè¿¡ °üÇÑ ÁúÀÇÀÀ´ä
- ¿¹»ó Çã°¡»çÇ׿¡ °üÇÑ ÁúÀÇÀÀ´ä
¤· °ËÅäÀÇ°ß
- ±âÇÑ : 2017. 08. 07 (¿ù)±îÁö
- ¾ç½Ä : º°Ã·2.°ËÅäÀÇ°ß¼
- ¸ÞÀÏ : info@kobia.kr
ÁúÀÇÀÀ´äÁý(¾È) È®ÀÎ |
|
|
ÀÇ°ßÁ¶È¸ |
¼¼°èº¸°Ç±â±¸(WHO) ¹ÙÀÌ¿À½Ã¹Ð·¯ PQ °¡À̵å¶óÀÎ µî °ËÅä ÀÇ°ß ¼ö·Å (~8/7±îÁö)
¤· ½ÄÇ°ÀǾàÇ°¾ÈÀüó´Â ¼¼°èº¸°Ç±â±¸(WHO) ¹ÙÀÌ¿ÀÀǾàÇ° Ç¥ÁØÈ ºÐ¾ß Çù·Â¼¾Åͷμ±¹Á¦ °¡À̵å¶óÀÎ Á¦.°³Á¤¿¡ °øµ¿À¸·Î Âü¿©ÇÏ°í ÀÖÀ¸¸ç, ÇöÀç »ý¹°ÀǾàÇ° °ü·Ã ±¹Á¦ °¡À̵å¶óÀÎÀÇ Á¦¤ý°³Á¤À» ÁøÇà ÁßÀÓ
- ´ë»ó
°¡. WHO Pilot procedure for prequalification of similar biotherapeutic products.
³ª. WHO Guidelines on submission of documentation for the pilot procedure for prequalification of similar biotherapeutic products approved by stringent regulatory authorties.
´Ù. WHO Guidelines on submission of documentation for the pilot procedure for prequalification of similar biotherapeutic products.
¶ó. Guidelines on procedures and data requirements for changes to approved biotherapeutic products.
¤· °ËÅäÀÇ°ß
- ±âÇÑ : 2017. 08. 07 (¿ù)±îÁö
- ¾ç½Ä : ºÙÀÓ4 / ºÙÀÓ6
- ¸ÞÀÏ : info@kobia.kr
°¡À̵å¶óÀÎ(¾È) È®ÀÎ |
|
ÀÚ·á |
¢º °¨¿°º´ ´ëÀ¯Çà µî¿¡ µû¸¥ »ý¹°ÀǾàÇ°ÀÇ ½Å¼Ó Çã°¡½É»ç ¾÷¹«¼öÇà ÀýÂ÷ [°ø¹«¿ø Áöħ¼]
¢º ¿ø·áÀǾàÇ°ÀÇ °³¹ß ¹× Á¦Á¶ Ç°Áú½É»ç °¡À̵å¶óÀÎ [¹Î¿øÀÎ ¾È³»¼] °³Á¤ |
|
|
|
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
ÁÖ½Äȸ»ç
ÀÎÅÚ¸²ÄÚ¸®¾Æ |
20170801 |
Áߵ ³»Áö ÁßÁõ ¾ÆÅäÇÇ ÇǺο°¿¡ ´ëÇÑ Æ®¶ö·ÎÅ°´©¸¿ ´Üµ¶¿ä¹ý ECZTRA 2 - Àü½Å¿ä¹ý Èĺ¸ÀÚÀÎ Áߵ ³»Áö ÁßÁõ ¾ÆÅäÇÇ ÇǺο° ½ÃÇè´ë»óÀÚ¿¡¼ Æ®¶ö·ÎÅ°´©¸¿ ´Üµ¶¿ä¹ýÀÇ À¯È¿¼º ¹× ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², À§¾à´ëÁ¶, Á¦3»ó ÀÓ»ó½ÃÇè |
3»ó |
Tralokinumab APFS |
(»ç)»ï¼º»ý¸í°øÀÍÀç´Ü »ï¼º¼¿ïº´¿ø |
20170731 |
ȯÀÚÀ¯·¡ÀÌÁ¾À̽ÄÁ¾¾çÀ» °®°í ÀÖ´Â PD-L1 ¹ßÇö ÀüÀ̼º ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¼ Pembrolizumab Ä¡·á |
4»ó |
Å°Æ®·ç´Ù |
Çѱ¹¿À³ë¾àÇ°°ø¾÷ÁÖ½Äȸ»ç |
20170731 |
ÀÌÀü Ä¡·á °æÇèÀÌ ¾ø°í ÀýÁ¦ ºÒ°¡´ÉÇÑ ÁøÇ༺, Àç¹ß¼º ¶Ç´Â ÀüÀ̼º ÆíÆò»óÇǼ¼Æ÷½Äµµ¾Ï ÀÓ»ó½ÃÇè´ë»óÀÚ¿¡¼ ´Ïº¼·ç¸¿+ÀÌÇʸ®¹«¸¿ ¶Ç´Â Ç÷ç¿À·Î¿ì¶ó½Ç+½Ã½ºÇöóƾ°ú º´¿ëÇÑ ´Ïº¼·ç¸¿ ´ë Ç÷ç¿À·Î¿ì¶ó½Ç+½Ã½ºÇöóƾ¿¡ ´ëÇÑ ¹«ÀÛÀ§¹èÁ¤ Á¦3»ó ÀÓ»ó½ÃÇè |
3»ó |
ONO-4538 |
Çѱ¹ÈÀÌÀÚ
Á¦¾à(ÁÖ) |
20170728 |
Àç¹ß¼º ¶Ç´Â ºÒÀÀ¼º ¹Ì¸¸¼º °Å´ë B ¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) ½ÃÇè´ë»óÀڵ鿡¼ ¸é¿ª ÀÛ¿ëÁ¦, ÈļºÀ¯ÀüÇÐÀû Á¶ÀýÁ¦, CD20 ±æÇ×Á¦ ¹×/¶Ç´Â ÀüÅëÀû ÈÇпä¹ýÀ» Æ÷ÇÔÇÏ´Â º´¿ë¿ä¹ý°ú ¾Æº§·ç¸¿(MSB0010718C)¿¡ ´ëÇÑ Á¦ 1B »ó ´Ù±â°ü ÀÓ»ó½ÃÇè |
1b»ó |
À¯Åä¹Ð·ç¸¿(Utomilumab), ¾Æº§·ç¸¿(Avelumab) |
Çѱ¹¾Æ½ºÆ®¶óÁ¦³×Ä«) |
20170726 |
ÀýµÇÁö ¾Ê´Â õ½ÄȯÀÚ¸¦ ´ë»óÀ¸·Î Áß°£¿ë·®¿¡¼ °í¿ë·® ÈíÀÔÇü ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å¿Í Áö¼Ó¼º ¥â2-È¿´ÉÁ¦ º´¿ë¿ä¹ý¿¡ Ãß°¡µÈ Benralizumab (MEDI-563)ÀÇ À¯È¿¼º ¹× ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇÑ ´Ù±â°ü, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², ÆòÇ౺, À§¾à ´ëÁ¶, Á¦III»ó ÀÓ»ó½ÃÇè
|
3»ó |
º¥¶ó¸®ÁÖ¸¿(MEDI-563) |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
BENLYSTA
BLA #761043 |
BELIMUMAB |
- |
GLAXOSMITHKLINE LLC |
07/20/2017 |
NITYR
NDA #209449 |
NITISINONE |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
CYCLE PHARMS LTD |
07/26/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Rixathon |
rituximab |
Arthritis, Rheumatoid
Leukemia,
Lymphocytic, Chronic,
B-Cell
Lymphoma,
Non-Hodgkin Microscopic Polyangiitis
Wegener Granulomatosis |
15/06/2017 |
Oxervate |
recombinant human Nerve Growth factor (rhNGF) |
Keratitis |
06/07/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03233724 |
The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Carcinoma,
Non-Small-Cell Lung
Lung Cancer
Non-Small Cell Lung Cancer |
Drug: Decitabine (DAC)
Drug: Tetrahydrouridine (THU)
Drug: Pembrolizumab |
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC) |
Phase 1
Phase 2 |
NCT03233854 |
CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia |
B Acute Lymphoblastic Leukemia
CD19 Positive
Diffuse Large B-Cell Lymphoma
Associated With Chronic Inflammation... |
Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration |
David Miklos
Stanford University |
Phase 2 |
NCT03233711 |
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer |
Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma... |
Biological: Nivolumab |
National Cancer Institute (NCI) |
Phase 2 |
NCT03232307 |
Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) |
Hematopoietic/Lymphoid Cancer
Mantle Cell Lymphoma |
Drug: Ibrutinib
Drug: Rituximab
Drug: Lenalidomide
Drug: Dexamethasone Sodium Sulfate |
M.D. Anderson Cancer Center
Celgene
Janssen Scientific Affairs, LLC |
Phase 2 |
NCT03233347 |
Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma |
Stage I Hodgkin Lymphoma
Stage IA Hodgkin Lymphoma.... |
Drug: Brentuximab Vedotin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Vinblastine |
Academic and Community Cancer Research United
National Cancer Institute (NCI) |
Phase 2 |
NCT03233698 |
Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery |
Metastatic Alveolar
Soft Part Sarcoma |
Drug: Atezolizumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study |
National Cancer Institute (NCI) |
Phase 2 |
|
|
Clinical.gov À¯·´ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
Nation |
NCT03232268 |
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies |
Acute Myeloid Leukemia|Myelodysplastic Syndromes |
Biological: HLA-mismatched microtransplantation |
Institut Paoli-Calmettes |
Phase 1 |
ÇÁ¶û½º |
|
|
Clinical.gov ÀϺ» |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03233217 |
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ¡Ã65 Years |
Influenza |
Biological: QIV-HD by IM
Biological: QIV-SD by SC
Biological: QIV-HD by SC |
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.|Sanofi |
Phase 1
Phase 2 |
|
|
|
|
|
|
|
|
|
|
|
|
Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø ±¹³»¿Ü ÆÄÆ®³Ê¸µ °æºñÁö¿ø»ç¾÷ °ø°í ¾È³» (AusBiotech, Bio-Europe) (Áö¿ø¸¶°¨ÀϽà 8¿ù 7ÀÏ(¿ù) 18:00) |
Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø¿¡¼´Â º¸°Ç»ê¾÷ºÐ¾ß ¿ì¼ö±â¼úÀÇ ±¹³»¿Ü ±â¼úÀÌÀü ±âȸ ¸¶·ÃÀ» À§ÇÏ¿©
±¹³»¿Ü ÆÄÆ®³Ê¸µ(AusBiotech,BiO-EUROPE) ÆÄÆ®³Ê¸µ °æºñÁö¿øÀ¸·Î Âü°¡µî·Ï ºñ¿ëÀÇ 50%¸¦ Áö¿øÇÏ°í ÀÖ½À´Ï´Ù. |
AusBiotech |
BIO-EUROPE 2017 |
ÀϽÃ: '17.10.25 (¼ö) ~ 27 (±Ý), (3ÀÏ°£)
Àå¼Ò: Adelaide Convention Centre, South Australia
µî·Ïºñ: ¾à 970,000¿ø Áö¿ø (Àü½ÃÂü°ü, ÆÄÆ®³Ê¸µ, ÄÁÆÛ·±½º, ºñÁî´Ï½ºÆ÷·³ µî) |
ÀϽÃ: '17.11.6 (¿ù) ~ 8 (¼ö), (3ÀÏ°£)
Àå¼Ò: Berlin, Germany
µî·Ïºñ: ¾à 1,500,000¿ø Áö¿ø (Àü½ÃÂü°ü, ÆÄÆ®³Ê¸µ, ÄÁÆÛ·±½º, ºñÁî´Ï½ºÆ÷·³ µî) |
|
¼¼ºÎ³»¿ë º¸±â |
|
|
CPhI & BioPh Korea 2017¡¹ Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°°ü ȸ¿ø»ç È«º¸Áö¿ø ¾È³»
º» Çùȸ´Â ±¹Á¦Çù·Â ÃßÁø»ç¾÷ÀÇ ÀÏȯÀ¸·Î ±Ý³â 8¿ù 22ÀÏ(È)ºÎÅÍ 3ÀÏ°£ ¼¿ï ÄÚ¿¢½º¿¡¼ °³ÃֵǴÂ
Á¦¾à¹ÙÀÌ¿À»ê¾÷ Àü¹®Àü½ÃȸÀÎ ¡¸CPhI & BioPh Korea 2017¡¹ ¿¡ Âü°¡ÇÕ´Ï´Ù.
ȸ¿ø»çÀÇ ±Û·Î¹ú ÁøÃâÀ» Áö¿øÇÏ°í Çѱ¹ ¹ÙÀÌ¿ÀÀǾàÇ°»ê¾÷À» ³Î¸® ÇØ¿Ü¿¡ È«º¸ÇÏ°íÀÚ,
Çùȸ ºÎ½º ³» ȸ¿ø»ç ¼Ò°³ÀÚ·á(¿µ¹® ºê·Î½´¾î)¸¦ ºñÄ¡ÇÏ°íÀÚ ÇÏ¿À´Ï
°ü½ÉÀÌ ÀÖÀ¸½Å ±â¾÷¿¡¼´Â Çùȸ·Î ±âÇÑ ³» ¼ÛºÎ¸¦ ºÎŹ µå¸®°Ú½À´Ï´Ù. |
ÀÌ¿¬Á¤ (02-725-8438 / yjlee@kobia.kr)
¹ß¼Û±âÇÑ: ~8/18ÀϱîÁö |
|
|
|
|
|
|
|
|